Vancomycin-d₁₂ TFA

Cat. No.: HY-B0671S: Data Sheet Handling Instructions
FAQs
Technical Support

Vancomycin-d₁₂ TFA is a deuterium labeled Vancomycin (HY-B0671). Vancomycin is an antibiotic for the treatment of bacterial infections. It acts by inhibiting the second stage of cell wall synthesis of susceptible bacteria. Vancomycin also alters the permeability of the cell membrane and selectively inhibits ribonucleic acid synthesis.

For research use only. We do not sell to patients.

Vancomycin-d<sub>12</sub> TFA Chemical Structure

Vancomycin-d₁₂ TFA Chemical Structure

Size	Price	Stock	Quantity
100 μg		Get quote 3 - 4 weeks 2 - 3 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
500 μg		Get quote 3 - 4 weeks 2 - 3 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31

Synthetic products have potential research and development risk.

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Vancomycin-d₁₂ TFA:

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

Biological Activity
Purity & Documentation
References
Customer Review

Description	Vancomycin-d₁₂ TFA is a deuterium labeled Vancomycin (HY-B0671). Vancomycin is an antibiotic for the treatment of bacterial infections. It acts by inhibiting the second stage of cell wall synthesis of susceptible bacteria. Vancomycin also alters the permeability of the cell membrane and selectively inhibits ribonucleic acid synthesis^[1]^[2]^[3].
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Vancomycin-d₁₂ TFA Related Antibodies
Molecular Weight	1575.35
Formula	C₆₈H₆₄D₁₂Cl₂F₃N₉O₂₆
Unlabeled CAS	1404-90-6
SMILES	O[C@@H]1[C@@H](O[C@@](O[C@@H](C)[C@H]2O)([H])C[C@@]2(N)C)[C@@H](O[C@H](CO)[C@H]1O)OC3=C(OC4=CC=C([C@H]([C@H]5NC(C(NC([2H])[2H])([2H])C([2H])([2H])C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O)O)C=C4Cl)C=C([C@](NC([C@@H](NC5=O)CC(N)=O)=O)([H])C(N[C@](C6=O)([H])C7=CC8=C(O)C=C7)=O)C=C3OC9=CC=C([C@H]([C@](C(N[C@@](C(O)=O)([H])C%10=C8C(O)=CC(O)=C%10)=O)([H])N6)O)C=C9Cl.OC(C(F)(F)F)=O
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (282 KB) Handling Instructions (2659 KB)
References	[1]. Rybak MJ, et al. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9. [Content Brief] [2]. Watanakunakorn C, et al. Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother. 1984 Dec;14 Suppl D:7-18. [Content Brief] [3]. Warren CA, et al. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrob Agents Chemother. 2013 Feb;57(2):689-96. [Content Brief]